Stryker Corporation (SYK) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.84, which beat the Zacks Consensus Estimate of $2.73 by 4%. The bottom line also improved 13.6% year over year. Our model estimate for the metric was pegged at $2.77 per share.GAAP EPS was $1.41, down 17.6% from the year-ago quarter’s level. The significant decline was primarily due to the impact of the Inari Medical acquisition and higher interest expenses. (Find the latest EPS estimates and surprises on Zacks Ear ...

Industry Overview - The Medical sector is experiencing a continued recovery in sales, with earnings increasing year over year by 4.7% on 9.4% higher revenues, although inflationary pressures and supply chain challenges persist [1][2] - The first-quarter earnings for the Medical sector are expected to improve by 35%, while sales are projected to increase by 7.8%, compared to the previous quarter's earnings growth of 13.4% and revenue growth of 9.4% [3] Medical Device Industry Insights - The medical device industry began 2025 with robust growth, driven by sustained demand for advanced healthcare solutions and the normalization of elective procedures, with the global market projected to reach $1.3 trillion by 2029 [4] - Challenges such as semiconductor shortages and workforce shortages in AI and robotics are impacting production and innovation [5] - Trade tensions, particularly U.S.-China tariffs, have increased operational costs for medical device manufacturers, with 75% of U.S.-marketed medical devices manufactured abroad [6] Company Performance Expectations - Becton Dickinson is expected to report strong second-quarter results, with a projected revenue growth of 16.3% year over year in its Medical division, although a slight dip of 1.3% is anticipated in the Life Sciences segment [8] - Cardinal Health is expected to show steady performance in its Pharmaceutical and Specialty Solutions segment, supported by strategic acquisitions, despite the impact of a key customer contract expiration [10] - Baxter International is projected to report moderate growth, with an estimated 6.6% sales growth in its Medical Products & Therapies segment, aided by operational recovery [11] - DexCom's outlook remains promising, with a full-year revenue guidance of $4.6 billion, driven by expanded U.S. prescriber coverage and strong international performance [12] - Stryker Corporation is expected to show strong growth across multiple segments, with projected U.S. and international sales reaching $4.74 billion and $1.59 billion, respectively [13]

Stryker Corporation (SYK) is scheduled to release first-quarter 2025 results on May 1, after market close. In the last reported quarter, the company delivered an earnings surprise of 3.62%. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)Q1 EstimatesThe Zacks Consensus Estimate for earnings is pegged at $2.73 per share, indicating an increase of 9.2% year over year.The consensus mark for revenues is pinned at $5.70 billion, implying growth of 8.8% from the prior-year reported figu ...